Corcept Therapeutics Chief Development Officer William Guyer sold 20,000 shares on July 7, 2026, realizing $1.9 million in gross proceeds at a weighted average price of $93.13 per share. The transaction was a cashless exercise of 20,000 options at a strike price of $21.65 followed by an immediate open-market sale, executed under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following the sale, Guyer directly holds 3,985 common shares, of which 1,599 are unvested restricted stock awards, while retaining 130,000 derivative securities in the form of stock options. The sale occurred against a backdrop of positive company developments, including the early FDA approval of Lifyorli for ovarian cancer and raised full-year revenue guidance to between $950 million and $1.05 billion, though first-quarter results showed a $31.8 million loss due to launch spending.
Corcept Therapeutics IncorporatedEarly FDA approval of Lifyorli for ovarian cancer and raised revenue guidance to $950M-$1.05B.